CD274 and non-small cell lung carcinoma: These findings suggest that the combination therapy involving camrelizumab and low-dose apatinib has promising efficacy with manageable safety, presenting a potentially valuable therapeutic approach for advanced non-squamous NSCLC patients, regardless of their PD-L1 expression status (145).